Bank of America’s NovoCure NVCR Stock Holding History

Bank of America’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-110,900	Closed	-$1.79M	–	8161
2023 Q3	$1.79M	Buy	110,900 +107,500	+3,162%	+$3.1M	﹤0.01%	4361
2023 Q2	$141K	Buy	3,400 +2,800	+467%	+$174K	﹤0.01%	6049
2023 Q1	$36.1K	Sell	600 -238,800	-100%	-$19.1M	﹤0.01%	6592
2022 Q4	$17.6M	Buy	239,400 +187,300	+360%	+$14.1M	﹤0.01%	2123
2022 Q3	$3.96M	Buy	52,100 +31,900	+158%	+$2.49M	﹤0.01%	3584
2022 Q2	$1.4M	Buy	20,200 +200	+1%	+$15.1K	﹤0.01%	4611
2022 Q1	$1.66M	Sell	20,000 -54,300	-73%	-$4M	﹤0.01%	4773
2021 Q4	$5.58M	Hold	74,300	–	–	﹤0.01%	3549
2021 Q3	$8.63M	Buy	74,300 +20,000	+37%	+$3.02M	﹤0.01%	3006
2021 Q2	$12M	Hold	54,300	–	–	﹤0.01%	2641
2021 Q1	$7.18M	Buy	54,300 +10,800	+25%	+$1.71M	﹤0.01%	3034
2020 Q4	$7.53M	Hold	43,500	–	–	﹤0.01%	2773
2020 Q3	$4.84M	Buy	43,500 +40,000	+1,143%	+$3.2M	﹤0.01%	2940
2020 Q2	$208K	Hold	3,500	–	–	﹤0.01%	5221
2020 Q1	$236K	Buy	+3,500	New	+$277K	﹤0.01%	4996

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Bank of America's NVCR Position: Q1 2026 in Review

Bank of America reduced its NovoCure (NVCR) stake by 50% in Q1 2026, selling an estimated $2.16M and leaving 170,013 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #4167.

Bank of America first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $36.3M in Q2 2021. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Bank of America held 170,013 shares of NovoCure worth $1.85M as of Q1 2026.
Bank of America sold 172,940 NovoCure shares in Q1 2026, an estimated $2.16M.
NovoCure made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4167 holding.
Bank of America first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
Bank of America's NovoCure position peaked at $36.3M in Q2 2021.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.